-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Börse DüsseldorfEURSymbol AB3A-
SAREPTA THERAPEUTICS INCBörse Börse DüsseldorfEURSymbol AB3A
-
SAREPTA THERAPEUTICS INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol AB3A
-
SAREPTA THERAPEUTICS INCBörse Gettex System der Börse MünchenEURSymbol AB3A
-
SAREPTA THERAPEUTICS INCBörse Quotrix System der Börse DüsseldorfEURSymbol AB3A
-
SAREPTA THERAPEUTICS INCBörse Börse StuttgartEURSymbol AB3A
-
ISIN US8036071004 WKN: A1J1BHUSDSymbol SRPT
-
EURSymbol AB3A
-
EURSymbol AB3A
-
EURSymbol AB3A
-
EUR
-
USD
-
Symbol AB3A
Währung
EUR
Börse
Börse Düsseldorf Zeitzone: Europe/Berlin
Firmenname
Sarepta Therapeutics, Inc
Marktkapitalisierung
6.114.303.552 (+- 18%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
7.186.607.104 oder 5.042.000.000
Mitarbeiter
953 (+- 22%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
743 oder 1.162 Mitarbeiter
EBITDA -362.892.000
PEGRatio 159.25
Buchwert 11.322
Entdecke die 6 ETFs in denen Sarepta Therapeutics, Inc am höchsten gewichtet ist Insgesamt in 10 ETFs enthalten
Dir gefallen die Informationen zu Sarepta Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Sarepta Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Sarepta Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Sarepta Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
56 News & Informationen zur Sarepta Therapeutics Aktie
PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday
On Wednesday’s PreMarket Prep, co-hosts Joel Elconin and Dennis Dick discussed the bullish chart setups in several tech stocks.
…
ETF Portfolio Partners, Inc. Buys Vanguard Intermediate-Term Corporate Bond ETF, Cirrus Logic Inc, Kansas City Southern, Sells Sarepta Therapeutics Inc, Autodesk Inc
ETF Portfolio Partners, Inc. Buys Vanguard Intermediate-Term Corporate Bond ETF, Cirrus Logic Inc, Kansas City Southern, Sells Sarepta Therapeutics Inc, Autodesk Inc, Stocks: VCIT,CRUS,KSU,SRPT,ADSK,, release date:Apr 15, 2021
3 Beaten-Down Biotech Stocks: Can They Recover?
These drugmaker stocks may have been hammered down to bargain-bin prices.
Sarepta Therapeutics (SRPT): Down 50%
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biotechnology company engaged in developing unique RNA-targeted therapies and gene therapies…
Sarepta Therapeutics (SRPT) Presents At 39th Annual J.P. Morgan Healthcare Conference – Slideshow (NASDAQ:SRPT)
Sarepta Therapeutics: It's Down But Not Necessarily Out (NASDAQ:SRPT)
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) — National law firm Barr Law Group is investigating the actions of the officers and board of directors of Sarepta …
Stocks making the biggest moves midday: Nio, Tesla, Roku, Lululemon & more
These are the stocks posting the largest moves midday on Jan. 11, 2021.
SRPT Investor Alert – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation
NEW YORK, NY / ACCESSWIRE / January 10, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ:SRPT).
Here's Why Sarepta Therapeutics Lost Support on Wall Street
Disappointing trial results caused a flock of analysts to drop their ratings on this biotech stock.
SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Fir
NEW YORK, Jan. 9, 2021 /PRNewswire/ –?Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta… | January 9, 2021
The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off
JPMorgan Chase & Co. CEO Jamie Dimon is to be among the keynote speakers at next week's J.P. Morgan Healthcare Conference.
After ending 2020 in …
The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off
JPMorgan Chase & Co. CEO Jamie Dimon is to be among the keynote speakers at next week's J.P. Morgan Healthcare Conference. After end…
SRPT INVESTIGATION ALERT: Bernstein Liebhard Is Investigating Sarepta Therapeutics, Inc. For Violations Of The Securities Laws
NEW YORK, Jan. 8, 2021 /PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims
SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws
/PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of…
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. for violations of the securities… | January 8, 2021
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.06% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.06%
Mid-Afternoon Market Update: Gold Dips 3.5%; Merus Shares Surge
Toward the end of trading Friday, the Dow traded down 0.27% to 30,956.01 while the NASDAQ rose 0.36% to 13,114.70. The S&P also rose, gaining 0.03% to …
SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. – SRPT
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. resulting from allegations that… | January 8, 2021
Why Tenet, CVS, Thermo Fisher And Sarepta Are Moving Today
Tenet Healthcare (NYSE: THC) shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to …
Mid-Day Market Update: Dow Falls 50 Points; Chimerix Shares Spike Higher
Midway through trading Friday, the Dow traded down 0.16% to 30,990 while the NASDAQ rose 0.60% to 13,146.50. The S&P also rose, gaining 0.14% to …
Stocks making the biggest moves midday: Tesla, Plug Power, U.S. Steel, Chipotle & more
Check out the companies making headlines in midday trading.
Why Solid Biosciences Stock Is Sinking Today
Blame it on Sarepta.
Why Sarepta Therapeutics Stock Is Crashing Today
The biotech announced disappointing results from a clinical study of its lead gene-therapy candidate.
SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging Today
Shares of SRPT stock are getting hammered on Friday after Sarepta Therapeutics reported negative results from a treatment trial.
Mid-Morning Market Update: Markets Mostly Higher; US Economy Loses 140,000 Jobs In December
Following the market opening Friday, the Dow traded up 0.07% to 31,063.52 while the NASDAQ rose 0.90% to 13,185.08. The S&P also rose, gaining…
Mid-Morning Market Update: Markets Mostly Higher; US Economy Loses 140,000 Jobs In December
Following the market opening Friday, the Dow traded up 0.07% to 31,063.52 while the NASDAQ rose 0.90% to 13,185.08. The S&P also rose, gaining 0.46% to …
ROCE Insights For Sarepta Therapeutics
During Q3, Sarepta Therapeutics's (NASDAQ:SRPT) reported sales totaled $143.92 million. Despite a 31.6% in earnings, the company posted a loss of …
Stock Alert: Sarepta Therapeutics Slips On Disappointing Gene-Therapy Study Results
Sarepta Therapeutics, Inc. (SRPT) shares are falling on Friday morning on disappointing results of its gene-therapy study. The precision genetic medicine research company said its study for the treatment of Duchenne muscular dystrophy did not achieve a statistical significance on the primary functional endpoint of improvement in total NSAA score compared to placebo at 48 weeks post-treatment.
Optimism About More Stimulus May Lead To Continued Strength On Wall Street
The major U.S. index futures are currently pointing to a higher open on Friday, with stocks likely to add to the strong gains posted in the previous session. The markets may continue to benefit from optimism that a Democrat-controlled government will lead to more fiscal stimulus and a better handling of the coronavirus vaccine rollout.
Tesla, Sarepta, Boeing: What to Watch When the Stock Market Opens Today
Stock futures are signaling strength at the end of a week of political strife.
Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new …
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, …
Stocks making the biggest moves in the premarket: Tesla, Micron Technology, Sarepta Therapeutics & more
The stocks making the biggest moves in premarket trading include Tesla, Micron Technology, Sarepta Therapeutics & more.
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 7) …
Tesla, Sarepta, Boeing: What to Watch When the Stock Market Opens Today
By James Willhite
Here's what we're watching ahead of the opening bell on Friday.
— U.S. stock futures ticked higher, with contracts tied to the S&P 500 up 0.3% a day after the… | January 8, 2021
Pre-market Movers In Healthcare Sector: MRUS, OGEN, JAGX, CVAC, SRPT…
What's moving these stocks in pre-market hours today?.
ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data
Today's Daily Dose brings you news about Alnylam's transthyretin-mediated (ATTR) amyloidosis trial results; Sarepta's mixed results of investigational gene therapy SRP-9001 in patients with Duchenne muscular dystrophy; Aldeyra's dry eye disease trial results; and Revance's anticipated milestones.
Get Ready For Health Care Stocks to Go Wild. How to Play Them.
Politics is the hot story of January, but health care might be the hot trade.
Unusual Options Activity Insight: Sarepta Therapeutics
On Monday, shares of Sarepta Therapeutics (NASDAQ: SRPT) saw unusual options activity. After the option alert, the stock price moved up to $171.68. …